Box 301: The total number of subjects screened, regardless of whether or not they were included in the study.
Introduction
Measurement of blood pressure is the commonest measurement made in clinical practice, and the interpretation of the figure resulting from that measurement has far-reaching implications for the individual in whom the technique is performed. If the measurement is erroneously low, for example, the patient may be denied the most valuable drug treatment to prevent future stroke and heart attack, whereas if, on the other hand, the measurement is erroneously high, the individual may be commenced on lifelong blood pressure lowering drugs unnecessarily. It is imperative, therefore, that the device being used to measure blood pressure is accurate and, because blood pressure is a complex haemodynamic variable, it is accepted that all blood pressure measuring devices must be validated independently in the clinical setting.
Validation of blood pressure measuring devices began in the 1980s with a series of ad hoc validation protocols on devices [1] . From the 1990s onwards, device validation became more structured with the publication of standards and protocols from the Association for the Advancement of Medical Instrumentation (AAMI) and the British Hypertension Society (BHS) [2] [3] [4] [5] [6] [7] . In 2002, the Working Group on Blood Pressure Monitoring of the European Society of Hypertension (ESH), which is composed of experts in blood pressure measurement, many of whom have considerable experience in validating blood pressure measuring devices, published the International Protocol, which simplified previous protocols and was based on evidence from a large number of validation studies [8] . The International Protocol was drafted in such a way as to be applicable to the majority of blood pressure measuring devices on the market. The validation procedure was therefore confined to adults over the age of 30 years (who constitute the majority of subjects with hypertension), and it did not make recommendations for special groups, such as children, pregnant women and the elderly, or for special circumstances, such as during exercise, or for abnormal pathophysiological circumstances, such as atrial fibrillation, or arterial stiffness as may occur in the elderly. The protocol did not preclude investigators and manufacturers from applying the International Protocol to assessment and validation in these circumstances. For full background information on this revision, it is recommended that investigators familiarise themselves with the original protocol, which can be downloaded directly from www.dableducational.org.
Initially, the results of validation studies were published in peer-reviewed journals and, every few years, 'state-ofthe-market' papers summarising device accuracy were published in general and specialised journals [9] . However, it became apparent that many of these publications were not accessible to many would-be purchasers of blood pressure measuring devices. To overcome this deficiency, the Working Group of the European Society of Hypertension launched the www.dableducational.org website in 2004. This now receives visits from over 5000 organisations in 100 countries in all continents.
Since the International Protocol was published in 2002, 78 reported studies have been analysed and this analysis is the evidence base for the changes being incorporated in the first revision of the International Protocol [1, 10] .
Because of the increasing ban on the use of mercurycontaining sphygmomanometers, there is a need for an equivalent standard device that does not contain mercury.
The following are the basic changes to the revised protocol:
(1) Forms replace free-text results so that all data must be standardised. (2) The age restriction is reduced from 30 to 25 years to facilitate recruitment. (3) Phase 1 has been removed, as this is now considered redundant. (4) As a consequence of improvements in technology, pass levels have been tightened. This is of benefit to manufacturers who strive to produce devices of the highest standard. (5) Controls on the distribution of observer measurements are introduced to ensure that the intended recruitment ranges are reasonably maintained throughout the full procedure. (6) Due to difficulties experienced in recruiting subjects in high ranges, the recruitment limits have been relaxed under certain conditions. Support facilities provided by the dablEducational website to assist validation studies are outlined in Appendix B.
Devices passing the stricter criteria of this revision will be classed as having passed ESH-IP2. It will supersede the original protocol [8] for new studies from 1st July 2010 and for publications from 1st July 2011.
The sphygmocorder [11, 12] option described in the previous protocol is not included because no validated model is currently available.
This protocol validation applies only to the recorded measurements and does not extend to average measurements or any other derived statistics.
Validation requirements

General requirements
Environment:
(1) The room should be at a comfortable temperature and there should be no noise or other influences that may cause disturbance, such as telephones and pagers.
(2) Ambient noise should not be at a level that could interfere with the auscultation of blood pressures.
Equipment:
(1) Two standard mercury sphygmomanometers, the components of which have been checked carefully before the study, are used as reference standards. They should be within 1 m of the observers who should be able to follow the menisci at eye level from 40 mmHg to 180 mmHg. (2) Bladders must be available so that, on each subject, there is one of sufficient length to encircle 80%-100% of the arm circumference [13] . (3) Good quality nonelectronic stethoscopes with wellfitting earpieces should be used.
Test device:
( If the device allows blood pressure measurement by more than one method (e.g. oscillometry and auscultation), then separate validation studies for each measurement method must be performed. (6) If there is an optional feature intended to assist measurement, such as a facility to mark a blood pressure, then separate validation studies must be performed with and without the facility.
Observer requirements
A supervisor and two observers are required. The following should be observed:
(1) Observers should have adequate hearing and sight.
(2) Observers should be trained and experienced in blood pressure measurement [14, 15] . (3) Observer measurements must be recorded to the nearest 2 mmHg.
Subject requirements
The requirements stated in this protocol refer to a study in the general adult population. Validation studies in specific groups may necessitate modification of these requirements and all such changes or additions should be clearly laid out in Form 1 -Device and Study Details. 
Accuracy requirements
The protocol classifies observer-device differences as in Form 3 -Study Results. When comparing and categorising these differences, they are categorised into one of four bands according to their rounded absolute values.
Accuracy is determined by the number differences in these ranges both for individual measurements (Part 1) and for individual subjects (Part 2). To pass, a device must achieve all the minimum Pass Requirements shown.
Accuracy is contingent on strict adherence to the protocol, and results from validations not adhering to this protocol may be called into question.
Validation procedure, analysis and report
The validation procedure and report should be carried out according to Forms 1-4. These are designed to produce a standard comprehensive and focussed report. It is imperative that all data are completed so that the report contains all of the information required. The agreement between the investigator and sponsor should state that a full report of the validation study will be published irrespective of the result.
A photograph of the validated device and cuff against a white background should be provided. 
Observers blinded from each other's readings and from the device readings
Enter protocol adjustments, as necessary, when the study population is not general with sex, age and blood pressure distribution stated in detail. These adjustments should be justified, with references where possible. Because children and adolescents have a wide range of body size and blood pressure levels, the sample size for a validation study should depend on the study inclusion criteria. Thus, for example, a 33-subject study would be appropriate only if a narrow age range of children is included. Larger samples should be analysed proportionally to the 33-subject sample.
Circle the correct option on each of the following or, if required, complete the explanation beside 'Other'.
Location
Method
Purpose Operation
Automatic: Cuff inflation, deflation and blood pressure determination are fully performed by the device automatically; Semi-automatic: Blood pressure determination is performed automatically but cuff inflation and/or deflation needs manual operation;
Manual: Blood pressure determination is performed by manually irrespective of inflation and deflation control.
Cuff details including arm circumference ranges (as recommended by the device manufacturer). 
Arm cuffs
Entry measurements
Ask the subject to relax for 10-15 min. Then make sure that the subject is seated with legs uncrossed and back supported. Ensure that the arm is supported at heart level. If a wrist device is being tested, the wrist must be supported according to the manufacturer's instructions. If the subject is not seated as described, the posture used must be recorded as a protocol adjustment. Each device measurement is compared to the nearer of the previous and next observer measurement. As described below, the smaller error is circled and the corresponding observer measurement is copied to aid the analysis. 223  224  225  226  227  228  229  230   231  232  233  234  235  236  237  238   239  240  241  242  243  244  245  246   247  248  249  250  251  252  253 If a printout of test device data is possible, print the device data for this subject and attach it to this form.
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Form 3 -Study results
The data from Form 2 -Subject Data for each subject should be appropriately analysed so that the results on this form can be completed. All references to boxes 201-289 refer to values obtained from all of the Forms 2 from the relevant subjects. All blood pressure measurements are in mmHg. Boxes 359: Enter the number of measurements that were repeated in the included subjects because observers were more than 4 mmHg apart.
In order to ensure a uniform distribution, there must be at least 22 measurements and at most 44 measurements (Boxes must be at most 19. If not, further recruitment will be necessary. Subjects to be excluded will be those whose pressures drifted from recruitment pressures.
The overall SBP range must be from ≤ 100 mmHg to ≥ 170 mmHg and the overall DBP range must be from ≤ 50 mmHg to ≥ 120 mmHg. If not, further recruitment will be necessary. Subjects to be excluded will be the last recruited within the relevant ranges.
The minimum number of replacements should take place. If a subject is replaced for either of these reasons, circle Distribution in Box 287 of Form 2 for that subject.
In validations carried out in specific populations requiring more than 33 subjects but with similar blood pressure distributions, similar proportions should be used. If the blood pressure distribution in the specific population differs from the standard distribution, ignore this 
Form 4 -Study report
Each device should be reported separately, even if more than one device is validated in the same study.
Title
It is important that the title conveys the nature of the validation both concisely and comprehensively. The title should read Validation CIRCUMSTANCE of the MANUFACTURER MODEL TYPE blood pressure monitor USE according to the European Society of Hypertension International Protocol revision 2010.
Where MANUFACTURER is the name of the manufacturer or brand. MODEL is the model number. If more than one number is used, the alternatives, including internal model numbers, should follow in parentheses. TYPE describes the nature of the monitor. This is typically upper arm, wrist or ABPM. If it is not an automatic monitor, it should also include an appropriate adjective such as manual, semi-automatic or hybrid. USE is optional but may supplement TYPE to describe the monitor's intended use. It could be general, for example upper arm monitors might be primarily intended 'for self measurement' or 'for clinic use', or specific, for example 'for clinic use in low resource settings'. Commas should be added for clarity. CIRCUMSTANCE is required only if the study is not carried out in a general population or where the subjects are not at rest. It should state the population, group or other factor that defines the applicability of the results. Commas should be added for clarity. Two examples are shown below and a third is shown in Appendix A.
Validation of the Gizmo ABC-01 ABPM blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010. Validation, in the elderly, of the Gizmo ABC-02 upper arm blood pressure monitor, for self measurement, according to the European Society of Hypertension International Protocol revision 2010.
Device details
This is taken from the Device details section of Form 1 -Device and Study Details. A digital photograph of the monitor used in the study should be included. Do not use a photograph, of a similar model, downloaded from the web or supplied by the manufacturers.
Methodology
This is described in two paragraphs and it contains the information in the Study details section of Form 1 -Device and Study Details.
Familiarisation
A brief description of the familiarisation session should be provided. Any difficulties should be reported.
Recruitment
The population should be outlined and the method of selecting the sample should be described. Difficulties in recruitment should be described and how they were overcome.
Procedure
Outline any adjustment to the protocol due to validation in a nongeneral population, or otherwise, and outline any other exceptional issues relating to the study. If the protocol was followed as written, this should be stated as follows: The European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults was followed precisely. The check boxes the Study Details section of Form 1 -Device and Study Details should both be ticked. If so, a sentence should state this as follows: Overseen by an independent supervisor, measurements were recorded by two observers blinded from both each other's readings and from the device readings. If not, it is likely to constitute a serious violation and needs to be explained.
Problems encountered (apart from recruitment issues), including device faults, should be described along with their resolutions. All problems should be put in the context of the stage in the validation: This would give the total number of subjects completed at that time e.g. the device fell onto a concrete floor after the 25th subject was completed. It was recalibrated and found not to have been damaged.
Results
The results will comprise the tables in Form 3 -Study Results along with a graphical presentation. No text should be added.
Plots
These are mean-difference plots [16, 17] and they should be exactly as shown in the example plot (Appendix A). The x-axis of these plots represents blood pressures in the systolic range 80 mmHg-190 mmHg and the diastolic range 30 mmHg-140 mmHg. The y-axes represent errors from -30 mmHg to +30 mmHg. Horizontal reference lines are drawn at 5 mmHg intervals from +15 mmHg to -15 mmHg. The mean of each device pressure and its corresponding observer pressure is plotted against their difference with a point. Differences greater than 30 mmHg are plotted at 30 mmHg. Differences less than -30 mmHg are plotted at -30 mmHg. The same scales should be used for both SBP and DBP plots.
Where points are superimposed, these should be indicated either by proportionately larger points or by different symbols.
Discussion
The possible effect of any problems encountered should be raised -even if this is to state that there was no effect. A brief comment should be given on the sample and, with reference to the plots, the distribution of pressures. This should include an account of how well the population is represented. If this is poor (for example, if the pressures in a blood pressure range are clustered within that range), an explanation of why a better sample could not be obtained must be provided along with justification for the applicability of the results. Where a special population is used, any adjustments not defined by the population should be justified. If Korotkov Phase IV was used, the effect of this on the accuracy of DBP should be discussed. If previously published validation studies exist for this device, their results should be briefly compared and contrasted to those of the current study.
Conclusion
The conclusion as to whether the device is accurate for use in the population should be stated. If the results are particularly sensitive to correct use (e.g. most wrist devices) then this caution must be stated.
Appendices Appendix A: Example of a completed validation report
Validation of the Acme A1 upper arm blood pressure monitor, for clinic use and self measurement, according to the European Society of Hypertension International Protocol revision 2010.
Methodology
Familiarisation
Twelve test-measurements were carried out. No problems were encountered.
Recruitment
Hypertensive subjects were recruited from those attending the hypertension clinic in the ABC Hospital. Some participated immediately and without appointment. Others attended the hospital specially. Normotensive subjects were recruited from accompanying relatives or friends and from hospital staff. There was some difficulty in recruiting subjects with DBP in the high range but, other than that, there were no problems. Patients on antihypertensive treatment attending the hospital were generally well controlled and therefore subjects in the high ranges had to be drawn mainly from new patients with some recruitment from those with renal disease. 
Screening and recruitment details
Procedure
The European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults was followed precisely. [1] Overseen by an independent supervisor, measurements were recorded by two observers blinded from both each other's readings and from the device readings. 
Plots
(1) The 2002 ESH International Protocol is available to download as a pdf file from www.dableducational.org [8] . This protocol outlines the history and development of validation protocol methodology. (2) Manufacturers are referred to the device equivalence procedure on www.dableducational.org [18] .
Manufacturers of blood pressure measuring devices may make modifications to a device, which has previously been successfully validated for accuracy, that do not affect its measurement accuracy. The modified device should not require further validation. The procedure for manufacturers to declare the equivalence of a modified device with a device that has been validated earlier is described. (4) Manufacturers are referred to the facility for applying for performance accreditation for devices that is additional to the accuracy criteria of the International Protocol on www.dableducational.org and www.pressionearteriosa.net [19] . Although standard validation protocols provide assurance of the accuracy of blood pressure monitors, there is no guidance for the consumer as to the overall quality of a device. The PA. NET International Quality Certification Protocol denotes additional criteria of quality for blood pressure measuring devices. At the end of the certification process, ARSMED attributes a quality index to the device and a quality seal with four different grades (bronze, silver, gold and diamond) which may be used on the packaging of the appliance or in advertising. A quality certification is released to the manufacturer and published on www.pressionearteriosa. net and www.dableducational.org.
Appendix B: Support facilities provided by the dablEducational website to assist validation studies
Discussion
Recruitment of subjects with high BP, in particular high DBP, proved to be extremely difficult and accounted for most of the extra screened subjects; this is reflected in the overall distribution, as shown in the DBP plot, in which most of the points are below 115 mmHg. Nevertheless, there is close to a perfect 33 points in each range and the distribution conditions are fulfilled. Therefore, this has had no effect on the result.
Conclusion
As the device has failed to reach the required standards, it is not recommended for personal or clinical use.
